Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AES (AES)

AES Restates Q2 and Q3 2024 Results Over $192 Million Impairment Overstatement

Mixed Impact 5 of 5 legal/regulatory Written later

AES said its unaudited financial statements for the second and third quarters of 2024 should no longer be relied upon, because impairment expense tied to the sale of its 47.3% stake in AES Brasil was overstated. The company included restated figures in its 2024 Form 10-K and reported a material weakness in internal controls, but said the restatement does not change full-year 2024 net income, EPS, or Adjusted EBITDA.

Key points

  • Impairment expense overstated by about $192 million for the three months ended June 30, 2024, and about $5 million for the three months ended September 30, 2024.
  • Cause: incomplete data used to estimate the fair value of AES Brasil's net assets after it was classified as held for sale in Q2 2024.
  • Full-year 2024 net income attributable to AES, EPS, and Adjusted EBITDA are unchanged, per the company.
  • AES will not file amended 10-Qs for the restated periods; figures are in the 2024 Form 10-K filed March 10, 2025.

The filing

CompanyAES (AES)
Form8-K, current report
Filed with the SECMar 10, 2025, 9:29 PM ET
Accession number0000950103-25-003226

Items reported: 4.02 Non-Reliance on Prior Financials

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 10, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.